In the second part of this roundtable series, Dr. Michael Atkins moderates a panel of oncology experts as they explore the role of biomarkers in determining treatment strategies for patients with advanced kidney cancer. The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA in guiding decisions between IO-IO and IO-TKI regimens. The conversation also highlights ongoing clinical trials, such as the OPTIC trial, which aims to tailor treatment based on gene expression profiles.
